210 likes | 440 Views
Global Disease Burden and the Access Gap. UAEM Introductory Seminar September 27, 2008 By Goldis Chami. Outline. Global Disease Burden Drug Pipeline Access Gap Research & Development Gap. Global Disease Burden: World Health Statistics. Life expectancy at birth:.
E N D
Global Disease Burdenand the Access Gap UAEM Introductory Seminar September 27, 2008 By Goldis Chami
Outline • Global Disease Burden • Drug Pipeline • Access Gap • Research & Development Gap
Global Disease Burden: World Health Statistics Life expectancy at birth:
Global Disease Burden: World Health Statistics Life expectancy at birth:
Global Disease Burden: Why? • Poverty - Basic nutrition and clean water - Shelter - Education - Basic Medical Care (Public Health) Essential Medicines
Global Disease Burden: World Health Statistics Mortality per 100,000 population
HIV/AIDS • 3.6 million living with the disease worldwide • Most of these individuals in sub-Saharan Africa • Has killed 25 M
Hepatitis B (HBV) • Viral, transmitted much the same as HIV • Cirrhosis of liver & liver cancer • Vaccine available, extremely effective • Not always available in LMI countries • In endemic areas, prognosis for HIV is worsened
Heart Disease • Deaths have declined by >50% in industrialized countries • 93% of morbidity and mortality from CVD in LMI countries
Essential Medicines • Fundamental to basic care • WHO lists 312 essential medicines • 33% of the world has no access *Cough*
Issues: The Access Gap • The systematic inability of individuals in developing countries to obtain existing and essential medicines • In poorest parts of Africa, nearly 50% have no access • < 4% in LMI countries get needed anti-retrovirals
What Causes the Access Gap? • PRICE: the consumption of medicines is sensitive to price, especially in the poorest countries • Price, in turn, is affected by PATENT STATUS • The most significant factor in lowering prices is the introduction of generics into a country – MSFO • Generic competition the single most important tool to remedy the access gap - Oxfam
Research & Development Gap • The massive underinvestment in medicines for neglected diseases, which primarily impact those in LMI countries • The 10/90 Gap • TB & tropical disease = 11.4% of the tropical disease burden • …but only 13 out of 1393 drugs targeted these
Research & Development Gap Cont’d • Current system fails to optimize existing meds & technologies for use in developing countries • Examples will come later • Diagnostic tools not appropriate
R&D Gap: African Sleeping Sickness • Most commonly used drug to treat = arsenic based, kills 5% of those treated. • New drugs needed, but none have been developed • Why? R&D system depends on patents & market-based incentives. • 5-7% of profits from LMI countries
R&D Gap The patent system leads R&D toward the most profitable disease and conditions, rather than toward diseases that cause the most morbidity and mortality.